Ignite Creation Date:
2024-05-05 @ 12:01 PM
Last Modification Date:
2024-10-26 @ 9:19 AM
Study NCT ID:
NCT00216697
Status:
COMPLETED
Last Update Posted:
2011-05-17
First Post:
2005-09-13
Brief Title:
An Extension Study to Provide Bortezomib to Patients With Relapsed or Refractory Multiple Myeloma Who Previously Participated in a Bortezomib Phase III Study and Who May Benefit From Re-Treatment With or Continuation of Bortezomib Therapy
Sponsor:
Janssen Pharmaceutical KK
Organization:
Janssen Pharmaceutical KK